DUS3L Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-engineered polyclonal population in which the DUS3L gene has been disrupted within the human non-small cell lung carcinoma line NCI-H1299. This loss-of-function model allows researchers to interrogate the role of the DUS3L dual-specificity phosphatase in MAPK signaling and NSCLC pathogenesis without the need for additional clonal isolation. The polyclonal format preserves the genetic diversity of the parental line, providing a robust substrate for comparative functional genomics and drug response studies.
NCI-H1299 is an epithelial cell line derived from a lymph node metastasis of a male patient with non-small cell lung carcinoma. It is extensively used to model key attributes of aggressive lung cancer, including metastatic dissemination, invasion, and resistance to conventional therapies. These cells harbor a genetic landscape that frequently includes MAPK pathway hyperactivation, making them an ideal context in which to study negative regulators like DUS3L. Knockout of DUS3L in this setting enables dissection of its tumor-suppressive functions and its interplay with oncogenic signaling.
Molecular function: DUS3L encodes a putative dual-specificity phosphatase implicated in dephosphorylating and attenuating MAP kinases ERK1/2, JNK, and p38. Under physiological conditions, DUS3L opposes the activation of the MAPK/ERK and JNK/p38 pathways, which are triggered by growth factor receptors such as EGFR and MET or by stress stimuli. The enzyme acts downstream of the RAS-RAF-MEK kinase cascade, and its loss is predicted to sustain the phosphorylation of ERK and JNK, thereby promoting the transcriptional activity of ELK1, c-Jun, and ATF2 and the induction of proliferation-associated genes like c-Fos. Scaffold proteins, including KSR1 and JIP, may organize these signaling complexes and influence DUS3L substrate access.
In the NCI-H1299 background, DUS3L knockout removes a critical inhibitory constraint on MAPK signaling, leading to enhanced cell proliferation, survival, and invasive capacity. This model is therefore valuable for investigating how dual-specificity phosphatases modulate NSCLC malignancy and for identifying compensatory mechanisms or synthetic vulnerabilities arising from unchecked MAPK activity. Comparative studies with wild-type NCI-H1299 cells can pinpoint DUS3L-dependent phosphorylation events and gene expression programs, providing insights for therapeutic strategies targeting the MAPK axis in lung cancer.
Applications for these cells include functional characterization of DUS3L, mechanistic studies of ERK and JNK pathway regulation, and evaluation of drug resistance. Representative assays encompass phospho-ERK and phospho-JNK western blotting, RT-qPCR analysis of MAPK target genes, MTT or BrdU proliferation assays, Transwell migration/invasion tests, and colony formation assays. The cells can also be used in xenograft tumor models to examine the impact of DUS3L loss on in vivo growth. For technical inquiries, please contact Ascent Research.
